Everolimus in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth.
PURPOSE: This phase II trial is studying how well everolimus works in treating patients with
relapsed or refractory mantle cell lymphoma.